Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison C Tree

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Clinical and Translational Radiation Oncology|January 23, 2025
Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international surveyJennifer Le Guévelou, Paul Sargos, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2023
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice GuidelinesSun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
International Journal of Radiation Oncology, Biology, Physics|August 26, 2023
Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver VariabilityKobika Sritharan, Hafid Akhiat, Declan Cahill, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized TrialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology|February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate CancerWilliam A Hall, Eric Paulson, Brian J Davis, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical and Translational Radiation Oncology|January 23, 2025
Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international surveyJennifer Le Guévelou, Paul Sargos, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2023
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice GuidelinesSun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
International Journal of Radiation Oncology, Biology, Physics|August 26, 2023
Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver VariabilityKobika Sritharan, Hafid Akhiat, Declan Cahill, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized TrialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology|February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate CancerWilliam A Hall, Eric Paulson, Brian J Davis, et al.
Pageof 11